With colon cancer deaths rising among younger adults and millions of eligible Americans skipping their colonoscopies, Guardant Health is taking its Shield blood test on the road in hopes of tackling ...
The FDA has put a partial clinical hold on PepGen’s phase 2 mus | The FDA has put a partial clinical hold on PepGen’s phase 2 muscle wasting trial after reviewing preclinical data, continuing the stop ...
Oncology projects currently take up about 40% of Pfizer’s overall R&D budget. | After steering positive key pivotal readouts for a trio of Novartis’ blockbusters, Jeff Legos is now tasked with ...
Roche is plugging 710 billion won (about $484 million) into South Korea’s biopharma industry, with the goal of attracting ...
In an effort to boost global biopharma competitiveness, the U.K.’s National Institute for Health and Care Research (NIHR) has ...
Bayer has discontinued an early-stage clinical gene therapy for a rare genetic disorder in favor of a similar candidate. | Bayer has discontinued an early-stage clinical gene therapy for a rare ...
Nvidia, the computer chip giant, continues its deep dive into expanding artificial intelligence technology in the medtech and cancer research arenas, this time with diagnostics maker Droplet ...
U.S.-based RadNet is paying 215 million euros upfront, with another 15 million euros on the table tied to future milestones. RadNet plans to merge Gleamer with its 2020 DeepHealth buy, its artificial ...
UCB has entered the red-hot T-cell engager (TCE) space by paying $80 million for the rights to a Chinese biotech’s preclinical autoimmune candidate. At the center of the deal is ATG-201, a CD19/CD3 ...
Two weeks after Teva touted promising long-term data for its Sanofi-partnered bowel disease drug, the Israeli pharma ...
Ono Pharmaceutical subsidiary Deciphera Pharmaceuticals has dropped an early-stage candidate for advanced cancers from its ...
RGX-121 was rejected in early February, with Regenxbio listing the primary reasons given by the FDA as concerns about the ability to properly define a patient population, the use of a natural history ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results